the described population distributions of the markers, as measured in the two systems. The 95% con¢dence interval in such a modelling exercise with 50,000 Down's syndrome data-sets leads to a detection rate with a con¢dence interval of 70.3% at a 5% falsepositive rate. Thus, when the Kryptor and DPC detection rates as quoted in the paper are compared, the con¢dence interval for Kryptor is 61.7--62.3, while that for DPC is 57.7--58. 3 . Thus, the Kryptor has a signi-¢cantly higher detection rate than the DPC system.
The workers from DPC have made a number of basic errors and assumptions.
Firstly, they assume that the 60 cases were part of a much larger series of 210 cases published in 1999. 3 My paper quite clearly stated that the cases 'had been collected as part of routine ¢rst trimester screening of women of all ages in our centre over the past 5 years' (i.e. 1999--2004) --they were a collection after the 1999 study was published, and have no relationship to this earlier series.
Secondly, the rather dubious attempt at statistical manipulation of the cases, as if they had been part of the larger series to claim a greater concordance of detection rates between the two systems, is scienti¢cally and statistically £awed. The cases were not part of some larger series and in the paper in question I did not quote detection rates based on the cases themselves, but used the distribution parameters to model expected population detection rates. Thus, in a study of 60 samples, had I quoted the observed detection rate in the series, it would have been appropriate to quote a con¢dence interval, and indeed the con¢dence intervals of the two systems would have overlapped because of the small number of cases. However, this is not what was done --I quoted modelled detection rates based on 50,000 data-sets for the normal population and 50,000 for the Down's population. If Feddema et al. were aware of the literature, they would realize that such population modelling is standard practice and has been shown to be a robust method of getting closer to the 'true' detection rate achieved in routine screening.
While one would expect a company to attempt to put up a spirited defence of its assay, the 'smoke and mirrors' tactics do not hide the fact that, in this series of 60 cases of Down's Syndrome, the DPC assay had a 21.9% positive bias against the Kryptor assay, leading to a higher-than-expected median MoM, which will lead to a reduction in detection rate when used in combination with free b-hCG alone, or additionally with fetal nuchal translucency. The conclusions of my paper --'that better clinical performance is likely to be achieved with alternative platforms to the DPC IMMU-LITE 2000' --are therefore still valid. What DPC as a company should be concentrating on in their R&D facility is why this bias exists, perhaps looking at their choice of monoclonal antibodies in an attempt to improve clinical performance.
Kevin Spencer
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Geberhiwot et al. provided data to support the validity of the approach of combining forms of glycosylated haemoglobin (HbA 1c ) with fasting plasma glucose (FPG) in order to identify patients requiring an oral glucose tolerance test (OGTT). 1 In patients with FPG r6.0 mmol/L, an HbA 1c of 5.6% gave an optimal sensitivity of 72% and speci¢city of 77% to predict a 2 h plasma glucose of Z7.8 mmol/L. In the accompanying editorial, however, Kilpatrick states that it is di⁄cult to see how HbA 1c will ever supplant (or even complement) the measurement of glucose, while the latter test remains the single means by which the diagnosis is decided. 2 Remarkably, neither author refers to the largest national diabetes prevalence study in the developed world to have used OGTT, namely the Australian Diabetes, Obesity and Lifestyle Study 3 (AusDiab) and the Australian screening guidelines that were evaluated against these population data. 4 In brief, a national sample of 11,247 adults aged Z25 years underwent a 75 g OGTT. 3 The prevalence of diabetes was found to be 8.0% in men and 6.8% in women, with an additional 17.4% of men and 15.4% of women having impaired glucose tolerance or impaired fasting glycaemia. 3 The Australian screening guidelines identify risk factors as adults aged Z55 years or those aged Z45 years with modelled using standard statistical techniques for population modelling, using 50,000 data-sets for the normal and Down's populations derived from within the described population distributions of the markers, as measured in the two systems. The 95% con¢dence interval in such a modelling exercise with 50,000 Down's syndrome data-sets leads to a detection rate with a con¢dence interval of 70.3% at a 5% falsepositive rate. Thus, when the Kryptor and DPC detection rates as quoted in the paper are compared, the con¢dence interval for Kryptor is 61.7--62.3, while that for DPC is 57.7--58.3. Thus, the Kryptor has a signi-¢cantly higher detection rate than the DPC system.
HbA 1c or glucose for diabetes diagnosis?
Geberhiwot et al. provided data to support the validity of the approach of combining forms of glycosylated haemoglobin (HbA 1c ) with fasting plasma glucose (FPG) in order to identify patients requiring an oral glucose tolerance test (OGTT). 1 In patients with FPG r6.0 mmol/L, an HbA 1c of 5.6% gave an optimal sensitivity of 72% and speci¢city of 77% to predict a 2 h plasma glucose of Z7.8 mmol/L. In the accompanying editorial, however, Kilpatrick states that it is di⁄cult to see how HbA 1c will ever supplant (or even complement) the measurement of glucose, while the latter test remains the single means by which the diagnosis is decided. 2 Remarkably, neither author refers to the largest national diabetes prevalence study in the developed world to have used OGTT, namely the Australian Diabetes, Obesity and Lifestyle Study 3 (AusDiab) and the Australian screening guidelines that were evaluated against these population data. 4 In brief, a national sample of 11,247 adults aged Z25 years underwent a 75 g OGTT. 3 The prevalence of diabetes was found to be 8.0% in men and 6.8% in women, with an additional 17.4% of men and 15.4% of women having impaired glucose tolerance or impaired fasting glycaemia. 3 The Australian screening guidelines identify risk factors as adults aged Z55 years or those aged Z45 years with additional risk factors, or aged Z35 years in high-risk ethnic groups. Screening involves FPG measurement with FPG o5.5 mmol/L meaning diabetes unlikely, FPG Z7.0 mmol/L meaning diabetes likely and those in the range 5.5--6.9 mmol/L proceeding to OGTT. 4 When these guidelines were evaluated against the Aus-Diab population without known diabetes, this approach gave a sensitivity of 79.9% and speci¢city of 79.9% for identifying new diabetes. 4 The positive predictive value is 13.7% and one in ¢ve of the people screened need an OGTT. 4 When an HbA 1c Z5.3% is added to the algorithm (measured by boronate a⁄nity high-performance liquid chromatography), in a manner analogous to that suggested by Geberhiwot et al., sensitivity falls to 73.7%, whereas speci¢city increases to 89.2% and positive predictive value increases to 21.4%. 4 The proportion requiring OGTT falls from 20.7% to 11.6% of those screened. 4 The cost for detecting each person with newly diagnosed diabetes using the original protocol is Aus$746, which increases to Aus$828 when HbA 1c is factored into the algorithm in the manner suggested. 4 The practice of adding HbA 1c as a triage for those needing OGTT, as recommended by Geberhiwot et al., is a positive step. AusDiab 3 and the evaluation of the Australian screening guidelines 4 give valuable insights into the trade-o¡ between sensitivity, numbers requiring OGTT and costs per case of diabetes identi¢ed. Better decision-making can be facilitated through analysis of such data.
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